Adaptive Biotechnologies (HAM:1HM) 3-Year RORE % : -42.77% (As of Mar. 2026)


HAM:1HM Adaptive Biotechnologies Corp HAM:1HM
47 GF Score
Price €18.54
GF Value €8.80
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies 3-Year RORE %?

Adaptive Biotechnologies HAM:1HM -6.53% 47 3-Year RORE % is -42.77 as of Mar. 2026. GuruFocus rates HAM:1HM with a GF Score™ of 47/100 and a GF Value™ of €8.80 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Adaptive Biotechnologies ranks worse than 76.12% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Adaptive Biotechnologies's 3-Year RORE % for the quarter that ended in Mar. 2026 was -42.77%.

The industry rank for Adaptive Biotechnologies's 3-Year RORE % or its related term are showing as below:

HAM:1HM's 3-Year RORE % is ranked worse than
76.12% of 201 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.89 vs HAM:1HM: -42.77

Adaptive Biotechnologies  (HAM:1HM) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Adaptive Biotechnologies 3-Year RORE % Related Terms


Adaptive Biotechnologies 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies 3-Year RORE % Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only -6.01 10.70 4.73 -8.62 -38.69

Adaptive Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.74 -15.28 -25.65 -38.69 -42.77

HAM:1HM vs GRAL, WGS, RDNT: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Adaptive Biotechnologies's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's 3-Year RORE % falls into.


HAM:1HM
47GF Score
Adaptive Biotechnologies Corp HAM:1HM
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies 3-Year RORE % Calculation

Adaptive Biotechnologies's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.285--1.377 )/( -2.553-0 )
=1.092/-2.553
=-42.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -42.77 mean?
Adaptive Biotechnologies (HAM:1HM) has a 3-Year RORE % of -42.77 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #153 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 76.1%.
Is Adaptive Biotechnologies' 3-Year RORE % too high?
Adaptive Biotechnologies' current 3-Year RORE % is -42.77. Based on the distribution chart, Adaptive Biotechnologies ranks #153 out of 201 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Adaptive Biotechnologies has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' 3-Year RORE % compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #153 out of 201 companies for 3-Year RORE %. This places Adaptive Biotechnologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current 3-Year RORE % is -42.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (HAM:1HM) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.80, compared to a current price of €18.54 — trading 110.7% above its estimated fair value. The current 3-Year RORE % is -42.77. Adaptive Biotechnologies' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Adaptive Biotechnologies (HAM:1HM), the current 3-Year RORE % is -42.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (HAM:1HM) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of €18.54 is trading 110.7% above its estimated GF Value™ of €8.80. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for HAM:1HM:

  • 3-Year RORE %: -42.77
  • GF Value™: €8.80 vs. price of €18.54 (110.7% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the HAM:1HM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adaptive Biotechnologies Business Description

Other Exchanges ADPT:USA1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
47GF Score

Get the complete analysis for HAM:1HM

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.54
Price
€8.80
GF Value